INTRA-CELLULAR THERAPIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

ITEM 8.01 Other Events.

On June 29, 2020, Intra-Cellular Therapies, Inc. (the "Company") announced topline results from Study ITI-214-104, a Phase I/II translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1 (PDE1) inhibitor, in patients with chronic systolic heart failure with reduced ejection fraction (HFrEF).

The Company's press release announcing topline results from Study ITCI-214-104 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits


 Exhibit
 Number                                      Description

   99.1            Press release dated June 29, 2020

   104           Cover Page Interactive Data File (embedded within the Inline XBRL
                 document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses